Liu Xinyue, Li Xiaoliang, Liu Limin, Sun Xiao, Yu Zhe
Department of Paediatrics, Xingtai Central Hospital, Xingtai, Hebei 054000, China.
Department of Paediatrics, Xingtai Central Hospital, Xingtai, Hebei 054000, China
eNeuro. 2025 Apr 1;12(4). doi: 10.1523/ENEURO.0371-24.2025. Print 2025 Apr.
Attention-deficit/hyperactivity disorder (ADHD) adversely affects the learning, social interaction, and daily living of affected children. Atomoxetine (ATX) hydrochloride (HCI) has been widely used in clinical practice. Electroencephalogram (EEG) biofeedback, as a nonpharmacological treatment approach, has also demonstrated potential in improving symptoms in children with ADHD. We aimed to investigate the clinical efficacy of combining ATX HCI with EEG biofeedback in the treatment of ADHD in children. We hypothesized that this combined therapy would be more effective in alleviating symptoms in children with ADHD. Ninety children with ADHD were randomly separated into the control group (receiving ATX HCI treatment for 12 weeks) and study group (receiving ATX HCI treatment for 12 weeks combined with 60 sessions of EEG biofeedback treatment; = 45). Swanson, Nolan, and Pelham-IV (SNAP-IV) rating scale scores, integrated visual and auditory continuous performance test results, Conners parent symptom questionnaire (PSQ) scores, and adverse reactions were counted. After 12 weeks of treatment, SNAP-IV scores were lower in both groups and were much lower in the study group; full-scale attention quotient and full-scale response control quotient scores were elevated in both groups and were much higher in the study group; PSQ scores were lower in both groups and were much lower in the study group (all < 0.05). During the treatment period, there was no difference in the incidence of adverse reactions between both groups ( > 0.05). The treatment combination of ATX HCI and EEG biofeedback is effective for children with ADHD, improving their behavioral issues and psychological conditions.
注意缺陷多动障碍（ADHD）对受影响儿童的学习、社交互动和日常生活产生不利影响。盐酸托莫西汀（ATX）已在临床实践中广泛应用。脑电图（EEG）生物反馈作为一种非药物治疗方法，在改善ADHD儿童症状方面也显示出潜力。我们旨在研究盐酸托莫西汀与EEG生物反馈联合治疗儿童ADHD的临床疗效。我们假设这种联合治疗在减轻ADHD儿童症状方面会更有效。90名ADHD儿童被随机分为对照组（接受盐酸托莫西汀治疗12周）和研究组（接受盐酸托莫西汀治疗12周并结合60次EEG生物反馈治疗；每组 = 45）。统计斯旺森、诺兰和佩勒姆第四版（SNAP-IV）评定量表评分、综合视觉和听觉持续性操作测试结果、康纳斯父母症状问卷（PSQ）评分以及不良反应。治疗12周后，两组的SNAP-IV评分均降低，且研究组降低幅度更大；两组的全量表注意力商数和全量表反应控制商数评分均升高，且研究组升高幅度更大；两组的PSQ评分均降低，且研究组降低幅度更大（均P < 0.05）。治疗期间，两组不良反应发生率无差异（P > 0.05）。盐酸托莫西汀与EEG生物反馈联合治疗对ADHD儿童有效，可改善其行为问题和心理状况。
